Phase IV Protocol Submissions Should Not Have Time Limits, Merck Tells FDA

FDA should not impose time limits on submission of protocols for postmarketing studies, Merck's comments on FDA's draft guidance on postmarketing study status reports say.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet